<DOC>
	<DOCNO>NCT00262990</DOCNO>
	<brief_summary>The objective study assess safety efficacy patupilone compare pegylated liposomal doxorubicin . Additionally , study assess ability patupilone extend survival time potential beneficial effect woman nonresponsive recurrent ovarian , primary fallopian , primary peritoneal cancer .</brief_summary>
	<brief_title>Patupilone Versus Doxorubicin Patients With Ovarian , Primary Fallopian , Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>18 year age old Confirmed diagnosis ovarian , fallopian peritoneal cancer No three chemotherapy regimens Most recent regimen must platinum base Have unresolved bowel obstruction Have previous chemotherapy within 3 week Recovering surgery cause Other protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Epithelial ovarian cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cancer</keyword>
	<keyword>primary cancer</keyword>
	<keyword>recurrent cancer</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>taxane chemotherapy</keyword>
	<keyword>platinum chemotherapy</keyword>
	<keyword>Patupilone</keyword>
	<keyword>taxane platinum resistant</keyword>
</DOC>